Category - News

Markets

Lake Street analyst pitches Profound Medical as one of his ‘best ideas’ for 2025

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $17 target price on the company’s stock...

January 2, 2025

Executive Moves

Grown Rogue announces Andrew Marchington as CFO and corporate secretary

Grown Rogue (CSE:GRIN; OTC:GRUSF) has appointed Andrew Marchington as its chief financial officer (CFO) and corporate secretary, succeeding Ryan Kee effective January 1, 2025. Previously serving as senior vice president...

January 2, 2025

Executive Moves

Avalo names Jennifer Riley as CSO

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Jennifer Riley as chief strategy officer (CSO), a newly created role effective January 1, 2025. Ms. Riley will oversee corporate strategy, as well as...

January 2, 2025

Executive Moves

Karyopharm appoints Lori Macomber as EVP, CFO, and treasurer

Karyopharm Therapeutics (NASDAQ: KPTI) has announced the appointment of Lori Macomber as executive vice president (EVP), chief financial officer (CFO), and treasurer, effective January 3, 2025. Ms. Macomber, who will be...

January 2, 2025

Executive Moves

Veteran life science equity analyst Chad Messer joins Lake Street Capital Markets

Seasoned life science equity analyst, Chad Messer, Ph.D., has joined Lake Street Capital Markets as a managing director of equity research. Based in New York, Dr. Messer has over two decades of experience spanning...

January 2, 2025

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Executive Moves

Applied names John H. Johnson as EC; Shoshana Shendelman steps down as CEO

Applied Therapeutics (NASDAQ:APLT) has announced leadership changes, naming John H. Johnson as executive chairman (EC) and Les Funtleyder, formally CFO, as interim CEO. Shoshana Shendelman, MD, has stepped down from her...

December 20, 2024

Developments

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Mesoblast (ASX:MSB; NASDAQ:MESO) is rallying today after the company announced yesterday after market close that the FDA approved RYONCIL (remestemcel-L), an allogeneic (donor) bone marrow-derived mesenchymal stromal...

December 19, 2024

Executive Moves

Adicet appoints Julie Maltzman as CMO

Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025. Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with...

December 18, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Category - News

Subscribe